Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Study Identifier:
ALXN2050-MG-201
ClinicalTrials.gov Identifier:
EudraCT Identifier:
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Available Documents
Study Details
Medical Condition
- Generalized Myasthenia Gravis
- Myasthenia Gravis
Study Drug
- Drug: ALXN2050
- Drug: Placebo
Date
Apr 2022 - Nov 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 130 Years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
- Diagnosed with MG at least 3 months (90 days) prior to the date of the Screening Visit. Confirmation of MG must be made via the following:
- Positive serologic test for anti AChR antibodies at the Screening Visit, and
- Abnormal neuromuscular transmission demonstrated by single fiber electromyography or repetitive nerve stimulation, or
- Positive response to an AChEI test (eg, edrophonium chloride test), or
- Improvement of signs or symptoms related to MG during treatment with an oral AChEI, as determined by the treating physician
- Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at the Screening Visit.
- MG-ADL total score must be ≥ 5 (with at least 50% of the score attributed to non-ocular elements) at the Screening Visit and at randomization (Day 1).
- Participants receiving treatment with protocol-specified immunosuppressive therapies, corticosteroids, or acetylcholinesterase inhibitors must have been receiving treatment and on a stable dose prior to the date of the Screening Visit, with no changes to the regimen expected during screening, the PEP, and/or the ETP.
Exclusion Criteria
- Estimated glomerular filtration rate ≤ 30 milliliters/minute/1.73 squared meters during Screening calculated by Chronic Kidney Disease Epidemiology Collaboration.
- History of thymectomy, thymomectomy, or any other thymic surgery within 12 months prior to the Screening Visit.
- Any untreated thymic malignancy, carcinoma, or thymoma. Participants with a history of treated thymic malignancy or carcinoma are eligible for enrollment if they meet pre-specified conditions outlined in the protocol.
- Clinical features consistent with Clinical Deterioration at the time of the Screening Visit or at any time during the Screening Period prior to randomization (Day 1).
- Use of the following within the time periods specified below:
- Intravenous immunoglobulin G or subcutaneous immunoglobulin within the 4 weeks (28 days) prior to the Screening Visit.
- Use of tacrolimus or cyclosporine within the 4 weeks (28 days) prior to the Screening Visit.
Sex
Female & Male
Age
18 - 130 Years
Study Details
Medical Condition
- Generalized Myasthenia Gravis
- Myasthenia Gravis
Study Drug
- Drug: ALXN2050
- Drug: Placebo
Date
Apr 2022 - Nov 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 130 Years years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
- Diagnosed with MG at least 3 months (90 days) prior to the date of the Screening Visit. Confirmation of MG must be made via the following:
- Positive serologic test for anti AChR antibodies at the Screening Visit, and
- Abnormal neuromuscular transmission demonstrated by single fiber electromyography or repetitive nerve stimulation, or
- Positive response to an AChEI test (eg, edrophonium chloride test), or
- Improvement of signs or symptoms related to MG during treatment with an oral AChEI, as determined by the treating physician
- Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at the Screening Visit.
- MG-ADL total score must be ≥ 5 (with at least 50% of the score attributed to non-ocular elements) at the Screening Visit and at randomization (Day 1).
- Participants receiving treatment with protocol-specified immunosuppressive therapies, corticosteroids, or acetylcholinesterase inhibitors must have been receiving treatment and on a stable dose prior to the date of the Screening Visit, with no changes to the regimen expected during screening, the PEP, and/or the ETP.
Exclusion Criteria
- Estimated glomerular filtration rate ≤ 30 milliliters/minute/1.73 squared meters during Screening calculated by Chronic Kidney Disease Epidemiology Collaboration.
- History of thymectomy, thymomectomy, or any other thymic surgery within 12 months prior to the Screening Visit.
- Any untreated thymic malignancy, carcinoma, or thymoma. Participants with a history of treated thymic malignancy or carcinoma are eligible for enrollment if they meet pre-specified conditions outlined in the protocol.
- Clinical features consistent with Clinical Deterioration at the time of the Screening Visit or at any time during the Screening Period prior to randomization (Day 1).
- Use of the following within the time periods specified below:
- Intravenous immunoglobulin G or subcutaneous immunoglobulin within the 4 weeks (28 days) prior to the Screening Visit.
- Use of tacrolimus or cyclosporine within the 4 weeks (28 days) prior to the Screening Visit.
Protocol Summary
This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams \[mg\], 180 mg) in participants with generalized myasthenia gravis (gMG).
Safety will be monitored throughout the study.
Trial Locations
Location
Status
Location
Research Site
Phoenix, Arizona, United States, 85028
Status
N/A
Location
Research Site
Aurora, Colorado, United States, 80045
Status
N/A
Location
Research Site
Boca Raton, Florida, United States, 33487
Status
N/A
Location
Research Site
Port Charlotte, Florida, United States, 33952
Status
N/A
Location
Research Site
Tampa, Florida, United States, 33612
Status
N/A
Location
Research Site
Lexington, Kentucky, United States, 40508
Status
N/A
Go to page